Fundraising Fox

MinervaX

8 known investors

minervax.com ↗

MinervaX is a clinical-stage biotech company developing a prophylactic vaccine against Group B Streptococcus, with a lead candidate (AlpN GBS) in clinical trials for use in pregnancy and older adults. Its vaccine aims to prevent adverse pregnancy outcomes and life-threatening infections caused by Group B Streptococcus.

BiotechHealthtech

Investors · 8

Adjuvant CapitalNew York · $10M – $25M
IndustrifondenStockholm · $1.1M – $4.3M
LU InnovationLund
OrbiMedNew York · $1M – $75M
Pureos BioventuresPfäffikon
Sanofi VenturesCambridge · $5M
Sunstone CapitalFrederiksberg
EQT Life SciencesreportedLuxembourg · $11M – $66M

In the news

Our Investors | MinervaXminervax.com · Apr 2024Press Releases | MinervaXminervax.com · Apr 2024MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus | MinervaXminervax.com · Oct 2023Danish biotech startup MinervaX collects €72M to advance development of novel vaccine against Group B Streptococcus - ArcticStartuparcticstartup.com · Dec 2022MinervaX announces completion of 47.4 mEUR financing | MinervaXminervax.com · Dec 2020MinervaX - Drug Discovery World (DDW)ddw-online.com

Frequently asked questions

What does MinervaX do?
MinervaX is a clinical-stage biotech company developing a prophylactic vaccine against Group B Streptococcus, with a lead candidate (AlpN GBS) in clinical trials for use in pregnancy and older adults. Its vaccine aims to prevent adverse pregnancy outcomes and life-threatening infections caused by Group B Streptococcus.
Who are MinervaX's investors?
MinervaX's investors include Adjuvant Capital, Industrifonden, LU Innovation, OrbiMed, Pureos Bioventures, Sanofi Ventures, Sunstone Capital, EQT Life Sciences.